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Abstract: 
Objective: To describe 3 cases of clozapine toxicity associated with 
infectious and/or inflammatory processes.    
Case Summaries: 3 patients stable on clozapine therapy prior to a medical 
hospital admission developed clozapine toxicity.  It was suspected that an 
acute infectious and/or inflammatory process in each patient was related to 
abrupt mental status changes, onset of sialorrhea, myoclonus, and/or need 
for ventilatory support.  Investigations of altered mental status did not 
reveal alterative causes and presentations were not consistent with 
neuroleptic malignant syndrome, other acute neurologic complications, or 
psychiatric decompensation.  All patients improved after clozapine dose 
reductions allowing for transfer from intensive care units.  Using the 
Naranjo ADR Probability Scale for each case, a probable relation between 
clozapine toxicity and the infectious and/or inflammatory process was 
determined.          
Discussion: Clozapine toxicity may manifest with multiple symptoms 
including sedation, sialorrhea, and hypotension.  In addition to overdose 
and drug interactions; infection and/or inflammation may precipitate 
clozapine toxicity.  This may be related to cytokine-mediated inhibition of 
cytochrome P450 1A2.   The likelihood of toxicity via this mechanism has 
not been well-characterized, thus careful monitoring is required for 
medically ill patient receiving clozapine.  Clozapine is extensively bound to 
the acute phase reactant, alpha-1 acid glycoprotein, which may 
unpredictably protect against clinical toxicity.  C-reactive protein has also 
been investigated to relate clozapine toxicity to infection and/or 
inflammation.    
Conclusion: Clozapine toxicity developed in 3 patients admitted to a 
medical setting suspected to be related to infection and/or 
inflammation.  Clinicians should be aware of this potential adverse drug 
event with clozapine.  
  
 
 
http://mc.manuscriptcentral.com/aop
The Annals of Pharmacotherapy
For Peer Review
1 
 
Infection and inflammation leading to clozapine toxicity and intensive care: a case series 
 
Authors:  
Jonathan G Leung, PharmD, BCPS, BCPP 
Psychiatric Clinical Pharmacist, Department of Hospital Pharmacy Services 
Assistant Professor of Pharmacy, Mayo Clinic College of Medicine   
Mayo Clinic, Rochester, MN 
 
Sarah Nelson, PharmD, BCPS 
Critical Care Clinical Pharmacist, Department of Hospital Pharmacy Services 
Mayo Clinic, Rochester, MN 
 
Christopher R. Takala, DO 
Psychiatry Resident, PGY3, Department of Psychiatry and Psychology  
Mayo Clinic, Rochester, MN 
 
Jessica L. Gören, PharmD, BCPP          
Associate Professor, University of Rhode Island 
Psychiatric Pharmacist, Cambridge Health Alliance 
Instructor in Psychiatry, Harvard University 
Kingston, RI  
 
Corresponding Author: 
 Jonathan G Leung, PharmD, BCPS, BCPP 
Page 1 of 19
http://mc.manuscriptcentral.com/aop
The Annals of Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
Psychiatric Clinical Pharmacist, Department of Hospital Pharmacy Services 
Assistant Professor of Pharmacy, Mayo Clinic College of Medicine   
Mayo Clinic, Rochester, MN 
1216 Second Street SW, Rochester, Minnesota 55902 
Phone: 507-255-4109 
Fax: 507-255-7879 
Email: leung.jonathan@mayo.edu 
 
Key Words: Schizophrenia, Psychiatry, Psychotropics, Antipsychotics (Atypical), 
Toxicity 
Authors of this manuscript have no conflicts of interest or disclosures to declare.   
No funding was received in relationship to the development of this manuscript.   
Case #1 has been presented at the annual College of Psychiatric and Neurologic 
Pharmacists 2013; Colorado Spring, CO.  Case #2 has been presented at the annual the 
Society of Critical Care’s 43rd Critical Care Congress   
Word Counts 
Abstract: 248 
Main Text: 2622 
Number of references: 21 
Number of tables: 1 
Page 2 of 19
http://mc.manuscriptcentral.com/aop
The Annals of Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
 
Abstract 
Objective: To describe 3 cases of clozapine toxicity associated with infectious and/or 
inflammatory processes.   
Case Summaries: 3 patients stable on clozapine therapy prior to a medical hospital 
admission developed clozapine toxicity.  It was suspected that an acute infectious and/or 
inflammatory process in each patient was related to abrupt mental status changes, onset 
of sialorrhea, myoclonus, and/or need for ventilatory support.  Investigations of altered 
mental status did not reveal alterative causes and presentations were not consistent with 
neuroleptic malignant syndrome, other acute neurologic complications, or psychiatric 
decompensation.  All patients improved after clozapine dose reductions allowing for 
transfer from intensive care units.  Using the Naranjo ADR Probability Scale for each 
case, a probable relation between clozapine toxicity and the infectious and/or 
inflammatory process was determined.         
Discussion: Clozapine toxicity may manifest with multiple symptoms including sedation, 
sialorrhea, and hypotension.  In addition to overdose and drug interactions; infection 
and/or inflammation may precipitate clozapine toxicity.  This may be related to cytokine-
mediated inhibition of cytochrome P450 1A2.   The likelihood of toxicity via this 
mechanism has not been well-characterized, thus careful monitoring is required for 
medically ill patient receiving clozapine.  Clozapine is extensively bound to the acute 
phase reactant, alpha-1 acid glycoprotein, which may unpredictably protect against 
clinical toxicity.  C-reactive protein has also been investigated to relate clozapine toxicity 
to infection and/or inflammation.   
Page 3 of 19
http://mc.manuscriptcentral.com/aop
The Annals of Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
Conclusion: Clozapine toxicity developed in 3 patients admitted to a medical setting 
suspected to be related to infection and/or inflammation.  Clinicians should be aware of 
this potential adverse drug event with clozapine.  
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Introduction  
Clozapine is a second generation antipsychotic reserved for the management of 
treatment resistant schizophrenia.  For patients prescribed clozapine admitted to a 
medical hospital there are important considerations all clinicians should recognize.  Upon 
hospital admission clozapine adherence and dosage must be verified.  Due to potent 
alpha-1 antagonism, if interruption of therapy has been for greater than 48 hours 
clozapine should be re-titrated to avoid potentially fatal hypotension.
1
 Additionally, as 
clozapine is primarily metabolized via the cytochrome P450 isozyme 1A2 (1A2), 
knowledge of factors which decrease 1A2 activity is crucial to prevent toxicity.  These 
include smoking cessation and drug interactions.  There is also evidence that clozapine 
toxicity may occur in the setting of an acute infectious and/or inflammatory process as a 
result of reduced 1A2 activity (Table 1).
2-9
 Prior cases describing clozapine toxicity as a 
result of infectious and/or inflammatory processes have mostly involved respiratory 
infections; however involvement of gastrointestinal and urinary infections have also been 
described.   Symptoms of toxicity in the reported cases have been generally mild to 
moderate and included sedation, dizziness and confusion.  We report 3 cases in which 
acute infectious and/or inflammatory processes were believed to have been the inciting 
factor for clozapine toxicity and the need for intensive care.   
Case 1: 
  A 52 year-old female with chronic obstructive pulmonary disease (COPD), 
schizophrenia, pulmonary hypertension and coronary artery disease was transferred from 
an outside facility for management of an acute exacerbation of COPD.  Pertinent social 
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history obtained revealed a smoking history of 3 cigarettes daily.  Medications prior to 
admission included oxybutynin 20 mg, escitalopram 40 mg, aspirin 81 mg, 
albuterol/ipratropium, and fluticasone/salmeterol. Upon arrival to an intensive care unit 
(ICU) the patient was placed on bilevel positive airway pressure for ventilation (BiPAP) 
and treated with albuterol and intravenous steroids.  Intravenous azithromycin 500 mg 
daily was also initiated although a chest x-ray revealed no evidence of infection.  There 
was no fever at the time of admission and pertinent laboratory values from the outside 
facility included a white blood cell count (WBC) of 10,400 cells/mm3.  Arterial blood 
gases obtained before and after placement of BiPAP revealed a resolving respiratory 
acidosis, with a pCO2 of 98 and 80, and pH 7.22 and 7.27, respectively.      
Less than 24 hours after admission the patient was transferred to a general 
medicine unit.  Her clozapine dose (100 mg every morning and 350 mg at bedtime) and 
medication adherence were confirmed.  Clozapine was restarted after missing 24 hours of 
therapy; and on hospital day 2 she received a bedtime dose and 1 morning dose the 
following day.  Prior to the next evening dose the patient was found unresponsive and 
required intubation for airway protection.  During transfer to the ICU hypotension and 
myoclonus were reported.  Carbon dioxide retention narcosis was suspected initially, 
however a pCO2 level obtained at the time of decompensation was not significantly 
different from her baseline of 55-60 mmHg and pH was appropriately compensated at 
7.38.  Ammonia was below the level of detection and electrolytes were within normal 
limits.  Administration of naloxone and flumazenil had no effect on mental status; and an 
electroencephalogram was unremarkable.  During the initial hours of ICU care, frequent 
suctioning was required from newly developed sialorrhea.  With myoclonus, 
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hypotension, sialorrhea and obtundation, clozapine toxicity was suspected.  Serum 
clozapine and norclozapine levels obtained 36 hours after the patient’s last dose which 
were 1400 ng/mL (reference: 350-700 ng/mL) and 606 ng/mL, respectively (ratio 2.3:1).  
The patient was seen by neurology and psychiatry consult services who found no 
evidence of serotonin syndrome or neuroleptic malignant syndrome with 
recommendations to continue to hold clozapine.  The patient was extubated 24 hours after 
the episode of unresponsiveness and toxicity resolved over the next several days.  After 6 
held doses clozapine and norclozapine serum concentrations were 582 ng/mL and 379 
ng/mL, respectively (ratio 1.5:1).  Clozapine was restarted at 50% of the patient’s home 
dose with further medication adjustments to be completed as an outpatient.  Potential 
confounders related to this case include a potential interaction between azithromycin and 
clozapine.  However, azithromycin is not expected to impact the hepatic metabolism of 
other medications unlike other macrolides.
11
 Azithromycin has been shown to have no 
impact on theophylline pharmacokinetics, which is metabolized similarly as clozapine 
(i.e. via 1A2 and 3A4).
11, 12
 It is possible that smoking cessation contributed to toxicity; 
but it is unlikely that cession of 3 daily cigarettes after 48 hours would produce rapid 
toxicity requiring intubation.  Using the Naranjo ADR Probability Scale
13
 it was 
determined that there was a probable relation between the patient's COPD exacerbation 
and the onset of clozapine toxicity.         
Case 2:  
A 49 year-old non-smoking male was admitted for a planned total hip arthroplasty 
(THA) for debilitating hip pain.  His past medical history was significant for paranoid 
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schizophrenia and chronic mild renal insufficiency.  Six months prior the patient was 
hospitalized for a subarachnoid hemorrhage which was complicated by placement of a 
ventriculoperitoneal shunt for communicating hydrocephalus.  A WBC prior to admission 
was 10.0 cells/mm3 and daily medications included aripiprazole 15 mg, clozapine 400 
mg, divalproex sodium 500 mg and escitalopram 10 mg.  Prior to the procedure the 
patient was noted to be alert, oriented and in no apparent distress with exception of hip 
pain.  The THA was completed without complication; however the patient continued to 
be minimally arousable 2 hours after surgery.  This was initially thought to be due to 
opioid administration during the procedure and in the recovery unit.  The patient was 
given repeated boluses of naloxone with minimal effect.  Initiation of a naloxone 
continuous infusion also had no effect on mental status.  The patient required transfer to 
an ICU for observation and was placed on noninvasive ventilation for hypoxemia.  A trial 
of flumazenil and discontinuation of a psoas nerve block had no effect on sedation.  A 
computed tomography scan of the head was negative for any acute process or change 
from previous imaging.  On hospital day 2, clozapine was decreased to 300 mg daily.  A 
total valproic acid level was 19 mg/dL (reference: 50-120 mg/dL) and serum ammonia 
was below the detectable level.  The patient remained afebrile and there was no 
indication of infectious although WBCs on hospital day 3 and 4 were 14,800 cells/mm3 
and 13,000 cells/mm3, respectively.  With significant somnolence persisting on hospital 
day 4 and new sialorrhea noted, clozapine and norclozapine levels were obtained.  Eight 
hours following the last dose, clozapine and norclozapine levels were 1130 ng/dL and 
297 ng/dL, respectively (ratio 3.8:1).  No further dose adjustments to clozapine were 
made and the patient was discharged with gradually resolving somnolence.  With the 
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acute change in mental status post-operative it is possible the patient experienced a 
negative reaction to the anesthetic agents utilized.  Yet this does not fully explain the 
protracted sedation experienced by the patient plus the new onset of sialorrhea.  There 
were also no previous reports of adverse reactions to anesthetics.  Vancomycin and 
ceftriaxone were administered pre- and post-operatively which would not interact with 
clozapine.  There is literature suggesting that divalproex sodium may increase clozapine 
levels; however the patient had been on a stable medication regimen months prior to the 
surgery.  The patient did have a complicated neurologic history but no findings were 
found to explain the patient’s acute and prolonged sedation or sialorrhea.  A 
sedimentation rate and C-reactive protein (CRP) were obtained preoperative and were 21 
mm/hr (reference range 0-22 mm/hr) and 7.5 mg/L (reference range < 8.0 mg/L), 
respectively suggesting no acute inflammatory process or infection prior to surgery.  
Unfortunately these laboratory values were not obtained later during the admission.  A 
probable relation was determined between the onset of clozapine toxicity and surgical 
intervention using the Naranjo ADR Probability Scale.
13
  
Case 3:  
A 61 year-old female non-smoker was hospitalized for fever after a right hip 
fracture requiring surgical intervention twelve days prior.  Past medical included arthritis, 
schizophrenia, diabetes, hypertension and hypothyroidism.  Medications upon admission 
from a nursing home included clonazepam 0.5 mg daily, clozapine 100 mg each morning 
and 600 mg at bedtime and mirtazapine 7.5 mg at bedtime.  Empiric ceftriaxone was 
administered for an elevated WBC of 21,600 cells/mm
3
.  She was diagnosed with 
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pneumonia, urinary tract infection and cellulitis involving the right hip.  Antibiotic 
therapy was changed to vancomycin and ertapenem for a total of 8 days.  After the 
antimicrobial course was completed the patient was taken to the OR on the tenth day of 
admission for a right hip hemiarthroplasty revision.  A culture from the hip obtained 
during surgery grew extended-spectrum beta-lactamase producing Escherichia coli.  The 
patient was then continued on ertapenem 1 gram IV daily for 3 additional days post-
operatively.  One hospital day twenty-two, the patient developed sepsis with blood 
cultures positive for MRSA and vancomycin reinitiation with continued ertapenem.  Over 
the next 7 days the patient became increasingly somnolent and confused, leading up to a 
non-verbal state.  Prior to sepsis she was noted to be psychiatrically stable, mentating 
well with no communication problems.  To reduce psychotropic medications, mirtazapine 
was discontinued.  Due to ongoing sedation and non-verbal state, on day 38 of 
hospitalization, serum clozapine and norclozapine concentrations drawn prior to the 
morning dose were 4,318 ng/ml and 504 ng/ml, respectively (ratio 8.6:1).  The patient’s 
WBC at this time was 35,700 cells/mm
3
 with the treatment for sepsis still ongoing.  
Clozapine, which had been continued throughout the entire hospitalization, was 
decreased to 100 mg nightly and the patient’s mental status returned to baseline within 5 
days allowing for transfer from the ICU.  An aspartate aminotransferase prior to 
obtaining the clozapine level was found to be 53 IU/L (reference: 8-34 IU/L); and while 
an alanine transaminase was not available, drug accumulation due to liver dysfunction 
was not suspected.  There was also no concern for kidney dysfunction throughout 
admission.   
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The acute change in the patient’s mental status may have represented the onset of 
delirium rather than clozapine toxicity.  Critical illness, specifically sepsis in this case, 
and the continuation of clonazepam would be considered risk factors for delirium.  
Clozapine itself also has also been rarely associated with delirium, believed to be related 
to its anticholinergic properties.  However, there was a temporal relation between sepsis 
and mental status changes and then clinical improvement after a dose reduction.   Other 
medications administered during admission, including antibiotics would not have been 
expected to interact with clozapine.  It was probable that there was an association 
between the newly developed sepsis and clozapine toxicity as determined using the 
Naranjo ADR Probability Scale.
13
  
Discussion: 
These cases highlight the importance of understanding the potential impact of 
acute infectious and/or inflammatory processes on clozapine metabolism.  While 
inhibition of CYP450 pathways is often considered a result of drug-drug interactions, 
disease states may also affect these metabolic pathways.  In our cases, acute infectious 
and/or inflammatory processes were believed to have decreased clozapine metabolism 
leading to toxicity identified by both clinical symptoms and serum clozapine levels.  In 
clinical practice serum levels of 350 ng/mL are generally targeted to maximize clozapine 
efficacy with levels greater than 700 ng/mL being associated with increased sedation and 
seizure risk.
14
  All patients experienced significant sedation and although none had a 
documented seizure, one patient did develop myoclonus.  Myoclonus is a known adverse 
event of clozapine which may occur with usual dosing or be an indication of infection.
7
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Sialorrhea which occurs often during the usual course of clozapine treatment may be also 
explained by acute toxicity and occurred in cases 1 and 2 above.
10
  Extensive workup was 
conducted in all three cases to rule out other causes of mental status changes.  The 
presence for drug interactions was also investigated, noting that previous cases may have 
been confounded by the use of ciprofloxacin, a strong 1A2 inhibitor.  Ciprofloxacin 
should be avoided if other pharmacologic options are available to avoid significant 
clozapine-related adverse events.
15   
  Resolution of the toxicity occurred in a temporal relationship after decreasing or 
holding clozapine therapy.  Striking is that the patient (case 3) with the highest elevations 
in clozapine levels did not experience the greatest degree of clinical toxicity.  This 
phenomenon has been described by Espnes and colleagues in which a patient with a 
clozapine level of 9074 nmol/L (2965 ng/mL; conversion factor = 3.06)
 
experienced no 
clinical toxicity.
4, 16
  This elevation of clozapine levels was suspected to be related to 
infection with a lack of symptoms due to an increase also of alpha-1 acid glycoprotein 
(AGP).  Human AGP is an acute phase reactant and the primary protein that binds free 
clozapine.  With approximately 97% of clozapine protein bound, as both AGP and serum 
clozapine levels increase due to infection or inflammation, the net result would not yield 
an increase of free serum clozapine to produce toxicity.
1, 4
  Interestingly it has been noted 
that, the acute-phase reaction in response to tissue injury during surgery may be 
incomplete or absent and AGP levels may not rise, explaining the toxicity seen in case 
2.
17
 As the clinical presentation of the clozapine toxicity varied in all three cases, it is 
likely that the degree of AGP increased uniquely for each patient.  It has also been 
suggested that CRP may be useful to obtain in patients receiving clozapine.  Abou Farha 
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and colleagues stated that in the setting of suspected clozapine toxicity, infection should 
be ruled out as an inciting factor and that CRP is useful to distinguish between overdose 
and toxicity related to infection.
5
  Authors also suggest that elevated CRP may be the 
only clinical sign of infection as clozapine may blunt immune mediated increases of 
WBC or development of fever.
5
 Elevated CRP may also be associated with myocarditis 
and benign clozapine-induced fever.
18
 Unfortunately during suspected toxicity, AGP and 
CRP laboratory values were not available in our cases.     
The suspected mechanism linking clozapine toxicity and acute inflammatory 
and/or infectious processes is related to a direct decrease of 1A2 activity.  Activity of 
1A2 may be reduced by up to 90% due to increases of IL-6, interferon and TNF-α during 
acute infectious and/or inflammatory processes.
2, 5
 Strengthening this hypothesis is the 
fact that patients receiving theophylline, another medication significantly metabolized by 
1A2, are more likely to develop toxicity after the development of respiratory infections.
19 
The degree in which a clozapine dose should be adjusted in the setting of an acute 
infectious and/or inflammatory processes is unknown but it has been suggested that at 
least a 50% reduction may be necessary to avoid toxicity.
20
 If doses are reduced there 
should be careful documentation as to the rationale and close patient follow-up after 
resolution of the infection and/or acute inflammatory process.  The utility of serum 
clozapine levels to guide dose reductions during acute toxicity may be limited as they are 
often a “send-out” laboratory value.  When there is clear evidence of clozapine toxicity 
doses should be reduced with the guidance of psychiatric consultation.  However, 
clozapine serum levels may useful to establish a baseline and in a retrospective manner 
argue for the case of toxicity when coupled with clinical symptoms.  The ideal ratio of 
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clozapine to norclozapine is approximately 2:1 and a significantly greater ratio may be 
indicative of saturated metabolism or 1A2 inhbition.
21
 While clozapine levels are 
quantifiable it is important that clinicians remember that alarmingly elevated levels may 
occur without clinical signs of toxicity.  In these instances the most appropriate initial 
action would be to closely monitor for toxicity without a dose reduction and repeat 
clozapine levels after the acute infectious and/or inflammatory process resolves.   
Conclusion:  
Three patients developed clozapine toxicity thought to be associated with an acute 
infectious and/or inflammatory process.  Although there were symptoms of toxicity, dose 
reductions were delayed potentially prolonging the need for ICU care.  Patients that 
develop an acute infectious and/or inflammatory process administered clozapine should 
be vigilantly monitored for toxicity.  Doses should cautiously be adjusted in the setting of 
significant clozapine toxicity with clinicians remembering serum clozapine levels may 
not equate to clinical toxicity.  Further study is needed to determine the role routine CRP 
and AGP monitoring.  
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Table 1. Additional cases describing clozapine toxicity associated with acute infectious 
and/or inflammatory processes  
Author  
(Year, n= ) 
Pathogenic Process CLZ Dose/ 
Range (mg) 
CLZ/NCLZ levels 
(ng/mL) 
Management/ 
Comments 
Darling, et al.
2
  
 (2011, n=3) 
URI, UTI 300-700  CLZ mean + SD: 
3085 + 1579 
- CLZ held; restarted        
5-90 days later 
deLeon, et al.
3
  
(2003, n=1) 
URI 600 CLZ: 1245  
NCLZ: 472 
- CLZ dose    
  decreased to 400 mg 
Espnes, et al.
4
 
(2012, n=1) 
Bacterial GI infection/ 
Crohn’s colitis 
900 CLZ: 3024 - No signs of toxicity 
- No dose change 
 - Ciprofloxacin 
prescribed 
Abou Farha, et 
al.
5
  
(2012, n=1) 
PNA 300 CLZ: 1301  
NCLZ: 515 
- CLZ stopped due to 
paralytic ileus 
Haack, et al.
6
 
(2003, n=4) 
PNA, unknown 
infection, viral illness 
300-600 CLZ mean + SD:  
1872 + 689 
NCLZ mean + SD: 
- CLZ stopped in all 
cases 
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521 + 190 
Liang, et al.
7
 
(2011, n=1) 
PNA 350 NR - Myoclonus and gait 
instability improved 
when CLZ decreased 
to 200 mg 
- CRP 201, WBC 
12,700 
Jecel, et al.
8
 
(2005; n=1) 
UTI  200 CLZ: 1066 
NCLZ: 379 
-CLZ decrease to 100 
mg and safely 
increased back to 200 
mg after infection 
resolution 
- CRP 81.5, WBC 
5,500 
Raaska, et al.
9
  
(2002, n=1) 
PNA 500 CLZ: 2074  Toxicity not reported 
 Dose reduced to 450 
mg  
 
CRP=C-reactive protein, GI = gastrointestinal; PNA = pneumonia; NR = not reported, 
URI = upper respiratory infection; UTI = urinary tract infection, WBC= white blood cell 
count 
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